胰激肽原酶联合硫辛酸治疗糖尿病视网膜病变临床观察  

Efficacy observation of kallidinogenase combined with lipoic acid in treatment of diabetic retinopathy

作　　者：罗春英[1] 王鸣鸿 吴建能[1] 李强翔 王华[3] 

机构地区：[1]广东省粤北人民医院内分泌科,广东韶关市512026 [2]湖南省老年医院,长沙市410016 [3]中南大学湘雅医院,长沙市41008

出　　处：《内科》2016年第2期171-173,共3页Internal Medicine

基　　金：国家自然科学基金项目(81170823);湖南省高层次卫生人才‘225’工程培养项目资助;湖南省中医药管理局2015年重点项目(201533);湖南省卫计委2015年计划项目(B2015-70);湖南省科技厅计划项目(2015JC3118)

摘　　要：目的观察胰激肽原酶联合硫辛酸胶囊治疗糖尿病视网膜病变(DR)的疗效。方法选择112例糖尿病视网膜病变患者,随机分为观察组和对照组各56例。两组患者均使用胰岛素控制血糖在正常范围。在此基础上,对照组患者口服胰激肽原酶片治疗,240 U/次,3次/d;观察组患者在同对照组治疗的基础上,口服硫辛酸胶囊治疗,0.6 g/次,1次/d。两组患者均治疗12周。评价两组患者的临床疗效,检测比较治疗前后两组患者血脂和血液流变学变化情况。结果观察组患者治疗总有效率(82.14%)显著高于对照组(64.29%),差异有统计学意义(P<0.05);观察组患者临床疗效优于对照组,差异有统计学意义(P<0.05)。治疗后,两组患者血脂与血液流变学显著改善(P<0.05),观察组血脂、血液流变学的改善明显优于对照组(P<0.05)。治疗过程两组患者均未出现明显毒副作用。结论胰激肽原酶联合硫辛酸治疗糖尿病视网膜病变临床疗效显著;硫辛酸可能具有降脂作用,与胰激肽原酶合用可有效改善DR患者血脂和血液流变学异常。ObjectiveTo observe the clinical effect of kallidinogenase combined with lipoic acid in treatment of diabetic retinopathy （DR）. MethodsA total of 112 patients with DR were randomly divided into observation group and control group, with 56 cases in each. Both groups were controled blood sugar in the normal range with insulin, besides, the control group was given oral kallidinogenase with the dose of 240U per time （three times a day） , while the observation group was given oral to lipoic acid with the dose of 0.6g per time （once a day） on the basis of the treatment of control group. Both groups were treated for 12 weeks, and the therapeutic effects were evaluated, changes of blood lipid microcirculation and hemorheology were observed before and after treatment. ResultsThe effective rate of observation group （82.14%） was significantly higher than that of control group （64.29%, P〈0.05）,and the curative effect of the observation group was superior to that of control group（P〈0.05）; compared with before treatment, the blood lipid and hemorheology in the two groups were improved significantly after treatment（P〈0.05）, and these indices in the observation group was superior to control group（P〈0.05）. No evident toxic effects was found in two groups during the course of therapy. ConclusionsThe clinical effect of kallidinogenase combined with lipoic acid in treatment of diabetic retinopathy is significant; lipoic acid may be can lower the level of lipid, and improve blood lipid microcirculation and hemorheology of DR while combined with kallidinogenase.

关 键 词：糖尿病视网膜病变 治疗 胰激肽原酶 硫辛酸 

分 类 号：R587.2[医药卫生—内分泌]